Imprecision of cardiac marker analyses among laboratories on the basis of external quality assurance results: Finnish experience

References

• World Health Organization. Report of the Fifth Working Group on the Establishment of Ischemic Heart Disease Registers. WHO, Copenhagen 1971
   Google Scholar
• Tunstall‐Pedoe H., Kuulasmaa K., Annouyel P., Arveiler D., Rajakangas A. M., Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Circulation 1994; 90: 583–612
   PubMed Web of Science ®Google Scholar
• Diagnosis of acute myocardial infarction by MONICA and FINMONICA diagnostic criteria in comparison with hospital discharge diagnosis. J Clin Epidemiol 1994; 47: 659–66
   PubMed Web of Science ®Google Scholar
• Alpert J., Thygesen K., et al. for the Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined – a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000; 36: 959–69
   PubMed Web of Science ®Google Scholar
• Panteghini M., Pagani F., Yeo K. T. J., Apple F. S., Christenson R. H., Dati F., et al. Committee on Standardization of Markers of Cardiac Damage of the IFCC. Evaluation of imprecision for cardiac troponin assays at low‐range concentrations. Clin Chem 2004; 50: 327–32
   PubMed Web of Science ®Google Scholar
• Zaninotto M., Sciacovelli L., Pagani F., Panteghini M., Plebani M. External quality assessment for biological markers of myocardial damage: an Italian experience. Clin Chem Lab Med 2004; 42: 1434–41
   PubMedGoogle Scholar
• Schumann G., Bonora R., Ceriotti F., Clerc‐Renaud P., Ferrero C. A., Ferard G., et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 2. Reference procedure for the measurement of catalytic concentration of creatine kinase. Clin Chem Lab Med 2002; 40: 635–42
   PubMed Web of Science ®Google Scholar
• Penttilä K., Koukkunen H., Halinen M., Punnonen K., Pyörälä K., Rantanen T., et al. Serum and plasma as alternative sample types in analysis of cardiac markers in the clinical routine. Scand J Clin Lab Invest 2002; 62: 553–60
   PubMedGoogle Scholar
• Penttilä I., Penttilä K., Rantanen T. Evaluation of the AxSYM troponin‐I assay in Finland. European Evaluation of the AxSYM Troponin‐I Assay, Abbott Diagnostic Division, G Schroeder. Wiesbaden‐Dengelheim, Germany 1998; 11–14, Abbott 52215
   Google Scholar
• Katruhka A., Bereznikova A., Pettersson K. New approach to standardization of human cardiac troponin I. Scand J Clin Lab Invest 1999; 49: 124–7
   Google Scholar
• Katrukha A. G., Bereznikova A. V., Esakova T. V., Pettersson K., Lövgren T., Severina M. E., et al. Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clin Chem 1997; 43: 1379–85
   PubMed Web of Science ®Google Scholar
• Katrukha A. G., Bereznikova A. V., Filatov V. L., Esakova T. V., Kolosova O. V., Pettersson K., et al. Degradation of cardiac troponin I: implication for reliable immunodetection. Clin Chem 1998; 44: 2433–40
   PubMed Web of Science ®Google Scholar
• Christenson R. H., Vaidya H., Landt Y., Bauer R. S., Green S. F., Apple F. A., et al. Standardization of creatine kinase‐MB (CK‐MB) mass assays: the use of recombinant CK‐MB as a reference material. Clin Chem 1999; 45: 1414–23
   PubMedGoogle Scholar
• Gerhardt W., Nordin G., Ljungdahl L. Can troponin T replace CK MBmass as “gold standard” for acute myocardial infarction “AMI”?. Scand J Clin Lab Invest 1999; Suppl 230: 83–9
   Google Scholar
• Christenson R. H., Duh S. H., Apple F. S., Bodor G. S., Bunk D. M., Dalluge J., et al. Standardization of cardiac troponin I assays: round Robin of ten candidate reference materials. Clin Chem 2001; 47: 431–7
   PubMed Web of Science ®Google Scholar
• Solymoss B. C., Bourassa M. G., Fortier A., Thereaus P. Evaluation and risk stratification of acute coronary syndromes using a low cut‐off level of cardiac troponin T, combined with CK‐MB mass determination. Clin Biochem 2004; 37: 286–92
   PubMedGoogle Scholar
• Collinson P. O., Wiggins N., Gaze D. C. Clinical evaluation of the ACS:180 cardiac troponin I assay. Ann Clin Biochem 2001; 38: 509–19
   PubMedGoogle Scholar
• Apple F. S., Quist H. E., Doyle P. J., Otto A. P., Murakami M. M. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology Consensus Recommendations. Clin Chem 2003; 49: 1331–6
   PubMed Web of Science ®Google Scholar
• Möckel M., Danne O., Schmidt A., Goldmann M., Müller C., Dietz R., et al. Reference values for cardiac troponins I and T in a goal‐oriented concept of health: cardiac marker values in a series of outpatients without acute coronary syndromes. Clin Chim Acta 2004; 342: 83–6
   PubMedGoogle Scholar
• Panteghini M. Recommendations on the use of biochemical markers in acute coronary syndrome: IFCC proposals. Available at: http://www.ifcc.org./ejifcc/vol14no2/1402062003014n.htm
   Google Scholar
• Hjortshøj S., Otterstad J. E., Lindahl B., Danielsen R., Pulkki K., Ravkilde J. Biochemical diagnosis of myocardial infarction evolves toward ESC/ACC consensus: Experiences from the Nordic countries. Scand Cardiovasc J 2005; 39: 159–66
   PubMed Web of Science ®Google Scholar
• Penttilä I., Penttilä K., Rantanen T. Laboratory diagnosis of patients with acute chest pain. Clin Chem Lab Med 2000; 38: 187–97
   PubMedGoogle Scholar
• Panteghini M. Selection of antibodies and epitopes for cardiac troponin immunoassays: should we revise our evidence‐based beliefs?. Clin Chem 2005; 51: 803–4
   PubMed Web of Science ®Google Scholar
• Sodi R., Darn S., Stott A. Time for troponin T? Implications from newly elucidated structure. Clin Chem 2004; 50: 786–7
   PubMedGoogle Scholar
• Salomaa V., Koukkunen H., Ketonen M., Immonen‐Räihä P., Kärjä‐Koskenkari P., Mustonen J., et al. for the FINAMI Study Group. A new definition for myocardial infarction: what difference does it make?. Eur Heart J 2005; 26: 1719–25
   PubMed Web of Science ®Google Scholar
• Jordanova N., Gyöngyösi M., Khorsand A., Falkensammer C., Zorn G., Wojta J., et al. New cut‐off values of cardiac markers for risk stratification of angina pectoris. Int J Cardiol 2005; 99: 429–35
   PubMedGoogle Scholar
• Pagani F., Stefini F., Panteghini M. Innotrac Aio! second‐generation cardiac troponin I assay: imprecision profile and other key characteristics for clinical use. Clin Chem 2004; 50: 1271–2
   PubMedGoogle Scholar
• Venge P., Johnston N., Lagerqvist B., Wallentin L., Lindahl B., and the FRISC‐II Study Group. Clinical and analytical performance of the Liaison cardiac troponin I assay in unstable coronary artery disease, and the impact of age on the definition of reference limits. A FRICS‐II Substudy. Clin Chem 2003; 49: 880–6
   PubMed Web of Science ®Google Scholar
• Christenson R. H., Cervelli D. R., Bauer R. S., Gordon M. Stratus® CS cardiac troponin I method: performance characteristics including imprecision at low concentrations. Clin Biochem 2004; 37: 679–83
   PubMed Web of Science ®Google Scholar
• Thomas M. A., Singh G. K., Williams E. J., McDowell I. F. W., Tovey J. A., Wayte A. M. O. A review of troponin assay performance in Wales: can the same (method‐dependent) decision limits be used in different sites?. Ann Clin Biochem 2005; 42: 351–6
   PubMedGoogle Scholar